Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15062) 15062
Publication (1675) 1675
Book Review (1443) 1443
Book Chapter (15) 15
Dissertation (10) 10
Book / eBook (7) 7
Conference Proceeding (7) 7
Magazine Article (6) 6
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14750) 14750
index medicus (14162) 14162
male (8504) 8504
female (8112) 8112
child (7067) 7067
hematology (6919) 6919
oncology (5925) 5925
adolescent (5754) 5754
child, preschool (5153) 5153
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (4381) 4381
adult (4351) 4351
precursor cell lymphoblastic leukemia-lymphoma - genetics (3843) 3843
infant (3293) 3293
leukemia (3280) 3280
cancer (3079) 3079
children (2985) 2985
precursor cell lymphoblastic leukemia-lymphoma - pathology (2768) 2768
middle aged (2712) 2712
precursor cell lymphoblastic leukemia-lymphoma - therapy (2660) 2660
acute lymphoblastic-leukemia (2460) 2460
pediatrics (2396) 2396
acute lymphoblastic leukemia (2380) 2380
acute lymphocytic leukemia (2180) 2180
prognosis (2170) 2170
abridged index medicus (2064) 2064
chemotherapy (2036) 2036
treatment outcome (1805) 1805
antineoplastic combined chemotherapy protocols - therapeutic use (1739) 1739
precursor cell lymphoblastic leukemia-lymphoma - complications (1580) 1580
precursor cell lymphoblastic leukemia-lymphoma - diagnosis (1578) 1578
risk factors (1552) 1552
precursor cell lymphoblastic leukemia-lymphoma - mortality (1502) 1502
aged (1497) 1497
animals (1438) 1438
precursor cell lymphoblastic leukemia-lymphoma - blood (1420) 1420
therapy (1414) 1414
research (1392) 1392
young adult (1315) 1315
acute myeloid-leukemia (1286) 1286
childhood (1280) 1280
recurrence (1273) 1273
remission induction (1265) 1265
transplantation (1253) 1253
precursor cell lymphoblastic leukemia-lymphoma - metabolism (1226) 1226
precursor cell lymphoblastic leukemia-lymphoma - immunology (1175) 1175
care and treatment (1160) 1160
retrospective studies (1140) 1140
genetic aspects (1132) 1132
mice (1097) 1097
health aspects (1084) 1084
expression (1073) 1073
analysis (976) 976
minimal residual disease (971) 971
disease-free survival (970) 970
acute lymphatic leukemia (967) 967
article (946) 946
antineoplastic agents - therapeutic use (888) 888
follow-up studies (881) 881
cell line, tumor (873) 873
risk (857) 857
immunophenotyping (814) 814
immunology (811) 811
flow cytometry (795) 795
survival rate (780) 780
transplantation, homologous (750) 750
hemic and lymphatic diseases (745) 745
diagnosis (739) 739
acute lymphocytic-leukemia (737) 737
relapse (726) 726
apoptosis (712) 712
medicine & public health (709) 709
time factors (707) 707
hematopoietic stem cell transplantation (705) 705
mutation (700) 700
hematology, oncology and palliative medicine (697) 697
gene expression (691) 691
survival analysis (680) 680
acute disease (677) 677
stem cells (673) 673
cells (665) 665
translocation, genetic (663) 663
precursor b-cell lymphoblastic leukemia-lymphoma - genetics (658) 658
infant, newborn (655) 655
case-control studies (648) 648
survival (642) 642
precursor cell lymphoblastic leukemia-lymphoma - epidemiology (635) 635
genetics & heredity (626) 626
bone marrow (618) 618
all (607) 607
polymerase chain reaction (607) 607
antineoplastic combined chemotherapy protocols - adverse effects (599) 599
t cells (599) 599
bone-marrow-transplantation (593) 593
precursor t-cell lymphoblastic leukemia-lymphoma - genetics (589) 589
bone marrow transplantation (588) 588
bone marrow - pathology (585) 585
lymphoma (579) 579
philadelphia chromosome (579) 579
combined modality therapy (572) 572
lymphatic leukemia (572) 572
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14352) 14352
Chinese (226) 226
Japanese (125) 125
Polish (72) 72
Russian (70) 70
Spanish (64) 64
German (57) 57
French (50) 50
Danish (10) 10
Dutch (10) 10
Czech (8) 8
Turkish (7) 7
Portuguese (6) 6
Hungarian (5) 5
Italian (5) 5
Korean (5) 5
Romanian (5) 5
Serbian (4) 4
Croatian (3) 3
Ukrainian (2) 2
Finnish (1) 1
Norwegian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
by Topp, Max S and Gökbuget, Nicola and Zugmaier, Gerhard and Klappers, Petra and Stelljes, Matthias and Neumann, Svenja and Viardot, Andreas and Marks, Reinhard and Diedrich, Helmut and Faul, Christoph and Reichle, Albrecht and Horst, Heinz-August and Brüggemann, Monika and Wessiepe, Dorothea and Holland, Chris and Alekar, Shilpa and Mergen, Noemi and Einsele, Hermann and Hoelzer, Dieter and Bargou, Ralf C
Journal of Clinical Oncology, ISSN 0732-183X, 12/2014, Volume 32, Issue 36, pp. 4134 - 4140
Purpose Patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis. CD19 is homogenously expressed in B-precursor ALL and... 
SALVAGE | ONCOLOGY | PROGNOSIS | INOTUZUMAB OZOGAMICIN | ACUTE LYMPHOCYTIC-LEUKEMIA | ADULTS | ANTIBODY | FAILURE | CHEMOTHERAPY | MRD | Recurrence | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Remission Induction | Neoplasm, Residual | Antibodies, Bispecific - therapeutic use | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Bispecific - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adolescent | Adult | Female | Aged | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
by Gökbuget, Nicola and Dombret, Hervé and Bonifacio, Massimiliano and Reichle, Albrecht and Graux, Carlos and Faul, Christoph and Diedrich, Helmut and Topp, Max S and Brüggemann, Monika and Horst, Heinz-August and Havelange, Violaine and Stieglmaier, Julia and Wessels, Hendrik and Haddad, Vincent and Benjamin, Jonathan E and Zugmaier, Gerhard and Nagorsen, Dirk and Bargou, Ralf C
Blood, ISSN 0006-4971, 04/2018, Volume 131, Issue 14, pp. 1522 - 1531
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission aftermultiagent therapy exhibit minimal residual... 
ALLOGENEIC TRANSPLANTATION | REDUCED-INTENSITY | RELAPSE | COMPLETE REMISSION | STANDARD-RISK | FREE SURVIVAL | ENGAGING ANTIBODY | HEMATOLOGY | MRD | CHEMOTHERAPY | CLINICAL-SIGNIFICANCE | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Humans | Middle Aged | Male | Survival Rate | Neoplasm, Residual | Disease-Free Survival | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Bispecific - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Bispecific - administration & dosage | Adolescent | Adult | Female | Aged | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
by Topp, Max S and Gökbuget, Nicola and Zugmaier, Gerhard and Degenhard, Evelyn and Goebeler, Marie-Elisabeth and Klinger, Matthias and Neumann, Svenja A and Horst, Heinz A and Raff, Thorsten and Viardot, Andreas and Stelljes, Matthias and Schaich, Markus and Köhne-Volland, Rudolf and Brüggemann, Monika and Ottmann, Oliver G and Burmeister, Thomas and Baeuerle, Patrick A and Nagorsen, Dirk and Schmidt, Margit and Einsele, Hermann and Riethmüller, Gert and Kneba, Michael and Hoelzer, Dieter and Kufer, Peter and Bargou, Ralf C
Blood, ISSN 0006-4971, 12/2012, Volume 120, Issue 26, pp. 5185 - 5187
Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in clinical relapse in patients with acute lymphoblastic leukemia (ALL).... 
CELL-ENGAGING ANTIBODY | ADULT PATIENTS | TRIALS | THERAPY | PROGNOSTIC-FACTORS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Follow-Up Studies | Humans | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Transplantation, Homologous | Neoplasm, Residual | Antibodies, Bispecific - therapeutic use | Disease-Free Survival | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Survival Analysis | Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404
by Asselin, Barbara L and Devidas, Meenakshi and Chen, Lu and Franco, Vivian I and Pullen, Jeanette and Borowitz, Michael J and Hutchison, Robert E and Ravindranath, Yaddanapudi and Armenian, Saro H and Camitta, Bruce M and Lipshultz, Steven E
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 8, pp. 854 - 862
To determine the oncologic efficacy, cardioprotective effectiveness, and safety of dexrazoxane added to chemotherapy that included a cumulative doxorubicin... 
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - blood | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Cardiotoxicity - blood | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cardiomyopathies - prevention & control | Male | Treatment Outcome | Cardiotoxicity - etiology | Dexrazoxane - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Cardiotonic Agents - administration & dosage | Troponin T - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Child | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Doxorubicin - adverse effects | Cardiomyopathies - chemically induced | Cardiotoxicity - prevention & control | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Expansion of highly cytotoxic human natural killer cells for cancer cell therapy
by Fujisaki, Hiroyuki and Kakuda, Harumi and Shimasaki, Noriko and Imai, Chihaya and Ma, Jing and Lockey, Timothy and Eldridge, Paul and Leung, Wing H and Campana, Dario
Cancer Research, ISSN 0008-5472, 05/2009, Volume 69, Issue 9, pp. 4010 - 4017
Infusions of natural killer (NK) cells are an emerging tool for cancer immunotherapy. The development of clinically applicable methods to produce large numbers... 
VITRO | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | PROLIFERATION | ACUTE MYELOID-LEUKEMIA | ALLOGENEIC NK CELLS | LIGAND INCOMPATIBILITY | ANTITUMOR-ACTIVITY | EXPRESSION | ADOPTIVE IMMUNOTHERAPY | BLOOD | Immunotherapy, Adoptive - methods | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Humans | Leukemia, Myeloid, Acute - blood | Leukemia, Myeloid, Acute - immunology | Mice, SCID | Animals | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | U937 Cells | K562 Cells | HL-60 Cells | Interleukin-2 - pharmacology | Killer Cells, Natural - immunology | Adult | Mice, Inbred NOD | Killer Cells, Natural - drug effects | Mice | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Leukemia, Myeloid, Acute - therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
by Mueller, Karen Thudium and Maude, Shannon L and Porter, David L and Frey, Noelle and Wood, Patricia and Han, Xia and Waldron, Edward and Chakraborty, Abhijit and Awasthi, Rakesh and Levine, Bruce L and Melenhorst, J. Joseph and Grupp, Stephan A and June, Carl H and Lacey, Simon F
Blood, ISSN 0006-4971, 11/2017, Volume 130, Issue 21, pp. 2317 - 2325
Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen... 
Recurrence | Humans | Middle Aged | Child, Preschool | Infant | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Monoclonal, Humanized - pharmacology | Adult | Bone Marrow Cells - drug effects | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Transgenes | Child | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Cytokines - blood | Antibodies, Monoclonal, Humanized - therapeutic use | Receptors, Antigen, T-Cell - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Tumor Burden - drug effects | Adolescent | Aged | Cell Proliferation - drug effects | Kinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Bone Marrow Cells - metabolism | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
by Moorman, Anthony V and Harrison, Christine J and Buck, Georgina A. N and Richards, Sue M and Secker-Walker, Lorna M and Martineau, Mary and Vance, Gail H and Cherry, Athena M and Higgins, Rodney R and Fielding, Adele K and Foroni, Letizia and Paietta, Elisabeth and Tallman, Martin S and Litzow, Mark R and Wiernik, Peter H and Rowe, Jacob M and Goldstone, Anthony H and Dewald, Gordon W and NCRI and Adult Leukaemia Working Party U and MRC and Eastern Cooperative Oncology Grp and Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute and on behalf of the Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group
Blood, ISSN 0006-4971, 04/2007, Volume 109, Issue 8, pp. 3189 - 3197
Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is... 
HYPER-CVAD | THERAPY | ABNORMALITIES | BCR-ABL | HYPODIPLOIDY | PROTOCOL | GROUP-B | HEMATOLOGY | CANCER | DELETIONS | LALA-94 | Chromosome Deletion | Multivariate Analysis | Humans | Risk Factors | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Survival Rate | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Karyotyping | Ploidies | Treatment Failure | Adult | Leukocyte Count | Philadelphia Chromosome | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients
by Armstrong, Jonathan K and Hempel, Georg and Koling, Susanne and Chan, Linda S and Fisher, Timothy and Meiselman, Herbert J and Garratty, George
Cancer, ISSN 0008-543X, 07/2007, Volume 110, Issue 1, pp. 103 - 111
BACKGROUND. Rapid clearance of poly(ethylene glycol)-asparaginase (PEG-ASNase) has been reported for up to one-third of patients treated for acute... 
asparaginase medac | antibody | poly(ethylene glycol) | acute lymphoblastic leukemia | Oncaspar | PEG‐asparaginase | Acute lymphoblastic leukemia | PEG-asparaginase | Antibody | Asparaginase medac | Poly(ethylene glycol) | COVALENT ATTACHMENT | lymphoblastic leukemia | MONOCLONAL-ANTIBODY | SERUM | CHILDHOOD | CHILDREN | ONCOLOGY | POLYETHYLENE-GLYCOL | PROTEINS | HEPATITIS-C | MODIFIED ALLERGENS | PEGYLATION | Flow Cytometry - methods | Reproducibility of Results | Humans | Polyethylene Glycols - pharmacokinetics | Male | Metabolic Clearance Rate | Treatment Outcome | Antineoplastic Agents - therapeutic use | Polyethylene Glycols - therapeutic use | Asparaginase - immunology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Agglutination Tests - methods | Antineoplastic Agents - adverse effects | Asparaginase - pharmacokinetics | Antibodies - blood | Female | Antineoplastic Agents - pharmacokinetics | Asparaginase - therapeutic use | Child | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Viral antibodies | Care and treatment | Lymphocytic leukemia | Polyethylene glycol | Patient outcomes | Antibodies | Dosage and administration | Research | Asparaginase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes
by Steven E. Lipshultz and Tracie L. Miller and Rebecca E. Scully and Stuart R. Lipsitz and Nader Rifai and Lewis B. Silverman and Steven D. Colan and Donna S. Neuberg and Suzanne E. Dahlberg and Jacqueline M. Henkel and Barbara L. Asselin and Uma H. Athale and Luis A. Clavell and Caroline Laverdière and Bruno Michon and Marshall A. Schorin and Stephen E. Sallan
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 10, pp. 1042 - 1049
Purpose Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might... 
C-REACTIVE PROTEIN | DEPENDENT FOLLOW-UP | CHILDHOOD-CANCER | BRAIN NATRIURETIC PEPTIDE | ONCOLOGY | CARDIOVASCULAR EVENTS | MYOCARDIAL INJURY | HIGH-DOSE CHEMOTHERAPY | CORONARY-HEART-DISEASE | PROGNOSTIC VALUE | TROPONIN-I | Humans | Antibiotics, Antineoplastic - adverse effects | Child, Preschool | Male | Cardiotonic Agents - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Cardiomyopathies - physiopathology | C-Reactive Protein - metabolism | Troponin T - blood | Time Factors | Peptide Fragments - blood | Female | Child | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Natriuretic Peptide, Brain - blood | Doxorubicin - administration & dosage | Heart - physiopathology | Echocardiography | Risk Assessment | Risk Factors | Ventricular Function, Left - drug effects | Treatment Outcome | Biomarkers - blood | Razoxane - therapeutic use | Antibiotics, Antineoplastic - administration & dosage | Heart - drug effects | Ventricular Remodeling - drug effects | Doxorubicin - adverse effects | Cardiomyopathies - chemically induced | Heart | Pediatrics | razoxane | Acute lymphatic leukemia | C-reactive protein | Risk groups | Cardiomyopathy | biomarkers | Inflammation | Doxorubicin | Troponin T | Children | Ventricle | Injuries | Index Medicus | Original Reports | Pedi2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
by Short, Nicholas J and Jabbour, Elias and Sasaki, Koji and Patel, Keyur and O'Brien, Susan M and Cortes, Jorge E and Garris, Rebecca and Issa, Ghayas C and Garcia-Manero, Guillermo and Luthra, Rajyalakshmi and Thomas, Deborah and Kantarjian, Hagop and Ravandi, Farhad
Blood, ISSN 0006-4971, 07/2016, Volume 128, Issue 4, pp. 504 - 507
The impact of achieving complete molecular response (CMR) in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remains undefined. We... 
ADULT PATIENTS | HYPER-CVAD | PHASE-2 | FLOW-CYTOMETRY | DASATINIB | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | IMATINIB MESYLATE | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Neoplasm, Residual | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Fusion Proteins, bcr-abl - blood | Vincristine - administration & dosage | Female | Philadelphia Chromosome | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Dexamethasone - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Vincristine - adverse effects | Methotrexate - administration & dosage | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations | Brief Report
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
by Zugmaier, Gerhard and Gökbuget, Nicola and Klinger, Matthias and Viardot, Andreas and Stelljes, Matthias and Neumann, Svenja and Horst, Heinz-A and Marks, Reinhard and Faul, Christoph and Diedrich, Helmut and Reichle, Albrecht and Brüggemann, Monika and Holland, Chris and Schmidt, Margit and Einsele, Hermann and Bargou, Ralf C and Topp, Max S
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 24, pp. 2578 - 2584
This long-term follow-up analysis evaluated overall survival (OS) and relapse-free survival (RFS) in a phase 2 study of the bispecific T-cell engager antibody... 
SALVAGE | ADULT PATIENTS | RELAPSE | THERAPY | ACUTE LYMPHOBLASTIC-LEUKEMIA | ACUTE LYMPHOCYTIC-LEUKEMIA | ANTIBODY BLINATUMOMAB | ENGAGING ANTIBODY | HEMATOLOGY | CANCER | CHEMOTHERAPY | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Salvage Therapy | Male | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Neoplasm, Residual | Young Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Allografts | Antineoplastic Agents - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | T-Lymphocyte Subsets - drug effects | Clinical Trials, Phase II as Topic - statistics & numerical data | Adult | Female | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Multicenter Studies as Topic - statistics & numerical data | Cytokines - secretion | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Remission Induction | Antibodies, Bispecific - therapeutic use | Disease-Free Survival | Antibodies, Bispecific - adverse effects | T-Lymphocyte Subsets - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Lymphocyte Count | Immunosuppressive Agents - adverse effects | Aged | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL
by Wood, Brent and Wu, David and Crossley, Beryl and Dai, Yunfeng and Williamson, David and Gawad, Charles and Borowitz, Michael J and Devidas, Meenakshi and Maloney, Kelly W and Larsen, Eric and Winick, Naomi and Raetz, Elizabeth and Carroll, William L and Hunger, Stephen P and Loh, Mignon L and Robins, Harlan and Kirsch, Ilan
Blood, ISSN 0006-4971, 03/2018, Volume 131, Issue 12, pp. 1350 - 1359
Early response to induction chemotherapy is an important prognostic factor in B-lymphoblastic leukemia (B-ALL). Here, we compare high-throughput sequencing... 
GROUP-STUDY AALL0232 | ONCOLOGY-GROUP | PROGNOSTIC-FACTORS | STANDARD-RISK | AIEOP-BFM | ACUTE LYMPHOBLASTIC-LEUKEMIA | BONE-MARROW | PERIPHERAL-BLOOD | STEM-CELL TRANSPLANTATION | HEMATOLOGY | CLINICAL-SIGNIFICANCE | Risk Assessment | Humans | Child, Preschool | Infant | Male | Survival Rate | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Neoplasm, Residual | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adolescent | Female | High-Throughput Nucleotide Sequencing | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Child | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia | 100
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia
by Lopez-Lopez, Elixabet and Ballesteros, Javier and Piñan, Maria A and Sanchez de Toledo, José and Garcia de Andoin, Nagore and Garcia-Miguel, Purificacion and Navajas, Aurora and Garcia-Orad, Africa
Pharmacogenetics and Genomics, ISSN 1744-6872, 02/2013, Volume 23, Issue 2, pp. 53 - 61
OBJECTIVESMethotrexate (MTX) is an important component of therapy for pediatric acute lymphoblastic leukemia (ALL). Treatment with MTX often causes toxicity,... 
toxicity | methotrexate | polymorphism | acute lymphoblastic leukemia | Prognosis | Humans | Male | Methotrexate - blood | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Haplotypes - genetics | Methotrexate - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antimetabolites, Antineoplastic - blood | Antimetabolites, Antineoplastic - adverse effects | Polymorphism, Single Nucleotide - genetics | Female | Biomarkers, Tumor - genetics | Retrospective Studies | Child | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Prognostic impact of soluble interleukin‐2 receptor level profiling in smoldering type adult T‐cell leukemia‐lymphoma
by Kubota, Ayumu and Nakano, Nobuaki and Tokunaga, Masahito and Miyazono, Takayoshi and Tokunaga, Mayumi and Makino, Torahiko and Takeuchi, Shogo and Yonekura, Kentaro and Takatsuka, Yoshifusa and Utsunomiya, Atae
Hematological Oncology, ISSN 0278-0232, 04/2019, Volume 37, Issue 2, pp. 223 - 225
SURVIVAL | ONCOLOGY | HEMATOLOGY | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - blood | Prognosis | Humans | Middle Aged | Receptors, Interleukin-2 - blood | Kaplan-Meier Estimate | Solubility | Male | Risk | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Disease Progression | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - classification | Aged, 80 and over | Female | Neoplasm Proteins - blood | Aged | Retrospective Studies | Lymphomas | Interleukins | T cells | Leukemia | Profiling | Lymphoma | Interleukin | Smoldering | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Prognostic miRNA classifiers in t cell acute lymphoblastic leukemia: Study protocol for a systematic review and meta-analysis of observational clinical studies
by Sabarimurugan, Shanthi and Madurantakam Royam, Madhav and Kumarasamy, Chellan and Kodiveri Muthukaliannan, Gothandam and Samiappan, Suja and Jayaraj, Rama
Medicine, ISSN 0025-7974, 03/2019, Volume 98, Issue 9, pp. e14569 - e14569
Background: The prognostic value of microRNA (miRNA) expression in T-cell acute lymphoblastic leukemia (T-ALL) has generated significant research interest in... 
SURVIVAL | DIAGNOSTIC-TEST ACCURACY | BIAS | meta-analysis | RISK | MICRORNAS | biomarker | systematic review | CANCER | MEDICINE, GENERAL & INTERNAL | publication bias | patients survival | hazard ratio | miRNA | TUMOR-SUPPRESSOR | prognosis and T-ALL | EXPRESSION | patients clinical outcomes | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - blood | Meta-Analysis as Topic | Prognosis | Humans | Risk Factors | Kaplan-Meier Estimate | Male | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Biomarkers, Tumor - blood | T-Lymphocytes - metabolism | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Systematic Reviews as Topic | Observational Studies as Topic | Female | MicroRNAs - blood | Research Design | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights